The aim of this study was to evaluate the changes in visual functional and anatomical outcomes of nAMD patients who experienced at least an 8-week treatment delay caused by COVID-19 and who were followed up after resuming anti-VEGF treatment during a year of regular treatment and to elucidate the reasons for these changes. The gene discussed is VEGFA; the disease is COVID-19.